Weiss Ratings Reaffirms Sell (E+) Rating for 23andMe (NASDAQ:ME)

Weiss Ratings reiterated their sell (e+) rating on shares of 23andMe (NASDAQ:ME) in a report published on Friday,Weiss Ratings reports.

23andMe Stock Performance

ME stock opened at $1.49 on Friday. The company’s 50-day simple moving average is $2.93 and its 200 day simple moving average is $4.25. 23andMe has a 52 week low of $1.34 and a 52 week high of $12.76. The company has a market capitalization of $39.97 million, a PE ratio of -0.10 and a beta of 1.19.

23andMe (NASDAQ:ME) last announced its quarterly earnings data on Tuesday, January 28th. The company reported ($1.02) earnings per share (EPS) for the quarter. 23andMe had a negative return on equity of 170.07% and a negative net margin of 183.39%.

Institutional Investors Weigh In On 23andMe

Large investors have recently bought and sold shares of the company. FNY Investment Advisers LLC acquired a new stake in shares of 23andMe in the 4th quarter valued at approximately $26,000. Leavell Investment Management Inc. acquired a new stake in shares of 23andMe in the 4th quarter valued at approximately $32,000. MassMutual Private Wealth & Trust FSB acquired a new stake in shares of 23andMe in the 4th quarter valued at approximately $40,000. Virtu Financial LLC acquired a new stake in shares of 23andMe in the 4th quarter valued at approximately $49,000. Finally, Geode Capital Management LLC boosted its stake in shares of 23andMe by 0.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,246,093 shares of the company’s stock valued at $1,476,000 after purchasing an additional 28,252 shares in the last quarter. 36.10% of the stock is currently owned by institutional investors and hedge funds.

About 23andMe

23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.